NY-IFF
25.6.2020 14:02:08 CEST | Business Wire | Press release
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today published its 2019 Sustainability Report, “Do More Good.” The title references a pillar of the Company’s purpose, To redefine how we live in and care for the resources of our world , which was launched last year as part of its most significant rebrand in 40 years. The report highlights IFF’s sustainability accomplishments throughout the business and covers the Company’s achievements in leveraging sustainable practices within its global footprint.
Andreas Fibig, IFF Chairman and CEO, said: “The leadership position that we have taken in sustainability is a reflection of the passion to do more good that’s been embraced by our people everywhere at IFF. We credit our customers, partners and suppliers for the incredible and productive alliances we have forged together in the service of sustainability. This is not a journey we can – or want - to take alone. It requires the energy and commitment of like-minded allies willing to challenge the status quo – and each other – to do what is ultimately best for people and planet.”
The 2019 report highlights include:
- IFF’s new purpose and Vision 2021 strategy, reflecting the importance of sustainability as a way of doing business at IFF
- External recognitions for IFF’s sustainability leadership, such as Barron’s, FTSE4Good, RobecoSAM Industry Mover award, Euronext Vigeo, and CDP A list
- Continued commitment to climate action, as demonstrated by the opening of the Union Beach, New Jersey solar array, the signing of the U.N. Business Ambition for 1.5°C: Our Only Future pledge, and strong progress against its environmental goals for greenhouse gas emission reductions (including a decrease in absolute emissions of 5.7% from prior year), and zero waste to landfill and water stewardship
- Strengthening of IFF’s responsible sourcing program and natural ingredient supply chains through new certifications, as well as by accelerating industry-leading blockchain technology as a tool for ensuring ingredient traceability
- Achieving an industry breakthrough in circular design and transparency with Henry Rose, a line of fine fragrances founded by actress Michelle Pfeiffer and created to the strictest environmental standards as defined by the Environmental Working Group and the Cradle to Cradle Products Innovation Institute
- External recognitions and certifications for IFF’s diversity & inclusion leadership, such as DiversityInc., Human Rights Campaign, EDGE, and the signing of the U.N. Global LGBTI Standards of Conduct for Business and the U.N. Women’s Empowerment Principles
- Accelerated the inclusion of legacy Frutarom data, where available, in response to stakeholder interest and to prepare for the anticipated merger with DuPont’s Nutrition & Biosciences business. This process included a significant data collection and training effort for more than 60 facilities in 27 countries.
Dr. Greg Yep, IFF’s Chief Scientific & Sustainability Officer, said, “IFF’s sustainability accomplishments are considerable and meaningful and I must thank our global network of green teams who are empowered to drive change for IFF and our communities. As pleased as we are with our results, from external recognitions to meeting and exceeding our goals, I know I speak for all of IFF when I confirm our commitment to continually improve and drive better outcomes, and always seeks ways to live up to our purpose and do more good.”
To read IFF’s 2019 Sustainability Report, visit iff.com/sustain and use #SustainxIFF to follow the conversation on its social channels.
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005417/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
